Interferon-alpha in the treatment of chronic myeloid leukemia. A summary and an update of the Italian studies.
Bone Marrow Transplant
; 17 Suppl 3: S11-3, 1996 May.
Article
in En
| MEDLINE
| ID: mdl-8769692
ABSTRACT
Six-hundred patients were recruited between 1986 and 1991 for studies of the treatment of Ph positive chronic myeloid leukemia (CML) with interferon-alpha (IFN-alpha). The median survival of the patients who were assigned to treatment with IFN-alpha was 6 years or longer than 6 years, and was more than the survival of the patients who were assigned to conventional chemotherapy. Survival prolongation was significantly related with the achievement of a cytogenetic response. IFN-alpha treatment was not harmful for subsequent allogeneic or autologous bone marrow transplantation.
Search on Google
Database:
MEDLINE
Main subject:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Interferon-alpha
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Guideline
/
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Humans
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Bone Marrow Transplant
Journal subject:
TRANSPLANTE
Year:
1996
Type:
Article
Affiliation country:
Italy